These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Novel nondopaminergic targets for motor features of Parkinson's disease: review of recent trials. Kalia LV; Brotchie JM; Fox SH Mov Disord; 2013 Feb; 28(2):131-44. PubMed ID: 23225267 [TBL] [Abstract][Full Text] [Related]
26. Noradrenaline in Parkinson's disease: from disease progression to current therapeutics. Fornai F; di Poggio AB; Pellegrini A; Ruggieri S; Paparelli A Curr Med Chem; 2007; 14(22):2330-4. PubMed ID: 17896981 [TBL] [Abstract][Full Text] [Related]
27. New pharmacologic horizons in the treatment of Parkinson disease. Bonuccelli U; Del Dotto P Neurology; 2006 Oct; 67(7 Suppl 2):S30-8. PubMed ID: 17030738 [TBL] [Abstract][Full Text] [Related]
28. Reevaluation of levodopa therapy for the treatment of advanced Parkinson's disease. Yokochi M Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S25-30. PubMed ID: 19131038 [TBL] [Abstract][Full Text] [Related]
29. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease. Chase TN Drugs; 1998; 55 Suppl 1():1-9. PubMed ID: 9483164 [TBL] [Abstract][Full Text] [Related]
30. Recent developments in the pharmacological treatment of Parkinson's disease. Tuite P; Riss J Expert Opin Investig Drugs; 2003 Aug; 12(8):1335-52. PubMed ID: 12882620 [TBL] [Abstract][Full Text] [Related]
32. Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson's disease. Fariello RG Drugs; 1998; 55 Suppl 1():10-6. PubMed ID: 9483165 [TBL] [Abstract][Full Text] [Related]
33. [Is the inhibition of adenosine A(2A) receptors an efficient way of Parkinson's disease treatment?]. Ceiślak M; Komoszyński M Neurol Neurochir Pol; 2006; 40(3):219-26. PubMed ID: 16794962 [TBL] [Abstract][Full Text] [Related]
34. Management of early Parkinson's disease. Hauser RA; Zesiewicz TA Med Clin North Am; 1999 Mar; 83(2):393-414, vi. PubMed ID: 10093585 [TBL] [Abstract][Full Text] [Related]
35. Antiparkinsonian drugs and their neuroprotective effects. Kitamura Y; Kakimura J; Taniguchi T Biol Pharm Bull; 2002 Mar; 25(3):284-90. PubMed ID: 11913520 [TBL] [Abstract][Full Text] [Related]
36. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease. Lindsay RM; Altar CA; Cedarbaum JM; Hyman C; Wiegand SJ Exp Neurol; 1993 Nov; 124(1):103-18. PubMed ID: 8282068 [TBL] [Abstract][Full Text] [Related]
37. [The treatment of Parkinson's disease--adenosine A2A receptor antagonists]. Matsubara E; Shoji M; Abe K Nihon Rinsho; 2002 Jan; 60(1):112-6. PubMed ID: 11808320 [TBL] [Abstract][Full Text] [Related]
38. Are dopamine receptor agonists neuroprotective in Parkinson's disease? Le WD; Jankovic J Drugs Aging; 2001; 18(6):389-96. PubMed ID: 11419913 [TBL] [Abstract][Full Text] [Related]
40. Novel models for Parkinson's disease and their impact on future drug discovery. Trigo-Damas I; Del Rey NL; Blesa J Expert Opin Drug Discov; 2018 Mar; 13(3):229-239. PubMed ID: 29363335 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]